MWNA
LUMO

Marshall Wace North America’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Marshall Wace North America’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-43,070
Closed -$3.88M – 1658
2017
Q3 		$3.88M Buy
+43,070
New +$3.3M 0.02% 623
2017
Q2 		– Sell
-11,934
Closed -$2.58M – 1490
2017
Q1 		$2.58M Buy
+11,934
New +$1.7M 0.02% 527

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's LUMO Position: Q4 2017 in Review

Marshall Wace North America sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 43,070 shares — an estimated $3.88M sold.

Marshall Wace North America first reported a position in LUMO in Q1 2017 and held it in 2 quarters. The position peaked at $3.88M in Q3 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • Marshall Wace North America reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 43,070 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $3.88M.
  • Marshall Wace North America first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Marshall Wace North America's Lumos Pharma, Inc. Common Stock position peaked at $3.88M in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.